Dimerix Ltd
Company Profile
Business description
Dimerix Ltd is a biopharmaceutical company developing new therapies in areas with unmet medical needs. The company is developing four product candidates: DMX-200 for FSGS; DMX-200 for diabetic kidney disease; DMX-200 for ARDS associated with COVID-19; and DMX-700 for COPD, as well as the proprietary ReceptorHIT assay technology. It pursues new product concepts and applies deep scientific knowledge to the discovery of products from early-stage development through to commercialisation. Dimerix products will target multiple territories. The Group has only operated in one Segment, being investment in research and development of biopharmaceutical drugs.
Contact
425 Smith Street
FitzroyVIC3065
AUST: +61 1300813321
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2026
Employees
9
Stocks News & Analysis
stocks
Avoid this overpriced ASX share
stocks
Markets brief: How will AI affect economic moats? Morningstar’s take on the new paradigm
stocks
Baidu: Moat downgraded to none from wide; AI segment growth to offset search decline in long \run
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,927.80 | 4.70 | -0.05% |
| CAC 40 | 7,915.36 | 78.13 | -0.98% |
| DAX 40 | 23,409.37 | 181.66 | -0.77% |
| Dow JONES (US) | 47,740.80 | 239.25 | 0.50% |
| FTSE 100 | 10,249.52 | 35.23 | -0.34% |
| HKSE | 25,817.37 | 408.91 | 1.61% |
| NASDAQ | 22,695.95 | 308.27 | 1.38% |
| Nikkei 225 | 54,477.81 | 1,749.09 | 3.32% |
| NZX 50 Index | 13,143.78 | 44.95 | 0.34% |
| S&P 500 | 6,795.99 | 55.97 | 0.83% |
| S&P/ASX 200 | 8,701.60 | 2.80 | -0.03% |
| SSE Composite Index | 4,108.58 | 11.97 | 0.29% |